Johnson & Johnson (JNJ) said Monday that new data from a phase 3 study of Tremfya, or guselkumab, showed its sustained clinical and endoscopic efficacy through week 92 in adults with moderately to severely active ulcerative colitis.
The company said 72% of patients treated with Tremfya were in clinical remission, with nearly all of them staying off steroid treatment for two months or longer, and 43% achieved endoscopic remission.
Among those who improved by week 44, 84% retained that progress through week 92, Johnson & Johnson said.
The outcomes were consistent regardless of prior exposure to biologic drugs or JAK inhibitors, according to the company.
No new safety issues were identified, and the drug's risk profile remained consistent with previous findings, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.